IMV to Participate in the BTIG Virtual Biotechnology Conference
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company focused on developing immunotherapies for hard-to-treat cancers, announced its participation at the BTIG Virtual Biotechnology Conference on August 9-10. The executive management team will engage in a fireside chat hosted by BTIG's research team on August 10 at 11:00 am (ET). A link to the presentation will be available in the investor section of IMV’s website for 30 days post-event. IMV is known for its lead candidate, maveropepimut-S, targeting survivin in various cancers.
- None.
- None.
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that members of IMV’s executive management team will be participating at the BTIG Virtual Biotechnology Conference which will be held on August 9-10 and will be participating in a fireside chat hosted by BTIG’s research team.
BTIG Virtual Biotechnology Conference Fireside Chat:
Tuesday, August 10 at 11:00 am (ET)
A link to this presentation will be available under “Events, Webcasts and Presentations” in the investors section of IMV’s website at the above-mentioned time and for approximately 30 days thereafter.
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as “will”, “may”, “potential”, “believe”, “expect”, “continue”, “anticipate” and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the Company’s ability to advance its development strategy, as well as the prospects, for its lead immunotherapy and its other pipeline of immunotherapy candidates. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful design and completion of clinical trials and the timely receipt of all regulatory approvals to commence, and then continue, clinical studies and trials and the receipt of all regulatory approvals to commercialize its products. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, the ability to access capital, the successful and, generally, the timely completion of clinical trials and studies and the receipt of all regulatory approvals as well as other risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing hard-to-treat cancer and other unmet medical needs. IMV is pioneering a novel class of cancer immunotherapies based on the Company’s proprietary delivery platform (DPX). This patented technology leverages a differentiated mechanism of action that generates a targeted and durable immune activation with limited side effects. IMV’s lead candidate, maveropepimut-S (formerly named DPX-Survivac), is a T cell-activating immunotherapy that combines the utility of the platform with a novel cancer target: survivin. IMV is currently assessing maveropepimut-S in breast and advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing another DPX-based immunotherapy: DPX-SurMAGE, a dual targeted immunotherapy to be evaluated in subjects with bladder cancer later this year. For more information, visit www.imv-inc.com and connect with us on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005153/en/
FAQ
When is IMV participating in the BTIG Virtual Biotechnology Conference?
What time is IMV's fireside chat at the BTIG Conference?
Where can I access IMV's presentation from the conference?
What is the focus of IMV's lead immunotherapy candidate?
What recent developments is IMV pursuing in immunotherapy?
